JAC Advance Access originally published online on March 28, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 1239-1246
© 2003 The British Society for Antimicrobial Chemotherapy
Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers
1 Department of Clinical Pharmacology, Pharmacia Corporation, 301 Henrietta Street, Kalamazoo, MI 49007; 2 Kalamazoo Center for Medical Studies, Michigan State University, Kalamazoo, MI, USA
Received 28 March 2002; returned 19 September 2002; revised 18 December 2002; accepted 21 January 2003
Aims: To determine the pharmacokinetics and tolerance of oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers following single- and multiple-dose administration.
Methods: In two randomized, double-blind, placebo-controlled, dose-escalating trials, subjects were exposed either to oral (375, 500 or 625 mg) or intravenous (500 or 625 mg) linezolid or placebo twice daily. Serial blood and urine samples were obtained after the first- and multiple-dose administrations for up to 18 days. Non-compartmental pharmacokinetic analyses were used to describe the disposition of linezolid.
Results: Plasma linezolid concentrations and area under the concentration–time curves increased proportionally with dose irrespective of the route of administration. Plasma linezolid concentrations remained above the MIC90 for susceptible target pathogens (4.0 mg/L) for the majority of the 12 h dosing interval. Mean clearance, half-life and volume of distribution were similar irrespective of dose for both the oral and intravenous routes. Linezolid was well tolerated and the frequency of drug-related adverse events was similar between the linezolid and placebo groups.
Conclusions: Oral and intravenous linezolid exhibit linear pharmacokinetics, with concentrations remaining above the target MIC90 for most of the dosing interval. These results support a twice-daily schedule for linezolid and demonstrate the feasibility of converting from intravenous to oral dosing without a dose adjustment.
Keywords: pharmacokinetics, linezolid, oxazolidinones, volunteers, Gram-positive, clinical trial
* Corresponding author. Tel: +1-269-833-1359; Fax: +1-269-833-1735; E-mail: gail.l.jungbluth{at}pharmacia.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. LaPlante and G. Sakoulas Evaluating Aztreonam and Ceftazidime Pharmacodynamics with Escherichia coli in Combination with Daptomycin, Linezolid, or Vancomycin in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4549 - 4555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Abe, K. Chiba, B. Cirincione, T. H. Grasela, K. Ito, and T. Suwa Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients J. Clin. Pharmacol., September 1, 2009; 49(9): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Williams, S. J. Brickner, C. K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J. H. Grosset, and E. L. Nuermberger Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis Am. J. Respir. Crit. Care Med., August 15, 2009; 180(4): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-J. Koh, O. J. Kwon, H. Gwak, J. W. Chung, S.-N. Cho, W. S. Kim, and T. S. Shim Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis J. Antimicrob. Chemother., August 1, 2009; 64(2): 388 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Williams, C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1314 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lovering, R. Le Floch, L. Hovsepian, J. Stephanazzi, P. Bret, G. Birraux, and C. Vinsonneau Pharmacokinetic evaluation of linezolid in patients with major thermal injuries J. Antimicrob. Chemother., March 1, 2009; 63(3): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schmidt, R. Banks, V. Kumar, K. H. Rand, and H. Derendorf Clinical Microdialysis in Skin and Soft Tissues: An Update J. Clin. Pharmacol., March 1, 2008; 48(3): 351 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Boak, J. Li, C. R. Rayner, and R. L. Nation Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro Model Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1287 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Myrianthefs, S. L. Markantonis, K. Vlachos, M. Anagnostaki, E. Boutzouka, D. Panidis, and G. Baltopoulos Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients Antimicrob. Agents Chemother., December 1, 2006; 50(12): 3971 - 3976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Leuthner, C. M. Cheung, and M. J. Rybak Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus J. Antimicrob. Chemother., August 1, 2006; 58(2): 338 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of Unbound Linezolid in Plasma and Tissue Interstitium of Critically Ill Patients after Multiple Dosing Using Microdialysis Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fiaccadori, U. Maggiore, C. Rotelli, R. Giacosa, E. Parenti, E. Picetti, P. Manini, R. Andreoli, and A. Cabassi Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1402 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Reyes, R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner, and S. S. Hegde Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4344 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Beringer, M. Nguyen, N. Hoem, S. Louie, M. Gill, M. Gurevitch, and A. Wong-Beringer Absolute Bioavailability and Pharmacokinetics of Linezolid in Hospitalized Patients Given Enteral Feedings Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3676 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Meyer, G. V. Kornek, M. Nikfardjam, G. D. Karth, G. Heinz, G. J. Locker, W. Jaeger, and F. Thalhammer Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration J. Antimicrob. Chemother., July 1, 2005; 56(1): 172 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dehghanyar, C. Burger, M. Zeitlinger, F. Islinger, F. Kovar, M. Muller, C. Kloft, and C. Joukhadar Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2367 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Whitehouse, J. A. Cepeda, R. Shulman, L. Aarons, R. Nalda-Molina, C. Tobin, A. MacGowan, S. Shaw, C. Kibbler, M. Singer, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill J. Antimicrob. Chemother., March 1, 2005; 55(3): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E Stein, S. L Schooley, C. A Peloquin, V. Kak, D. H Havlichek, D. M Citron, K. L Tyrrell, and E. J. Goldstein Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis Ann. Pharmacother., March 1, 2005; 39(3): 427 - 432. [Abstract] [Full Text] [PDF]
|
|